| Name | Title | Contact Details |
|---|
Prime Case LLC is a leading provider of lawsuit funding and lawsuit advances for those expecting a cash settlement resulting from a pending lawsuit, verdict or judgment. The need for our legal funding & settlement funding service arises from the fact that the legal process is often slow and many plaintiffs simply cannot afford to wait for a fair settlement due to financial pressures. Prime Case LLC works directly with attorneys and paralegals nationwide to provide their clients with immediate financial help. Our attorney-focused, the plaintiff funding process is the simple, fast, and cost-effective way to fund your clients. Here at Prime Case Funding, we want to save both you and your staff time to focus on getting your client the largest case settlement possible. Referring Your Clients to Prime Case Funding means: 1. Simple Application 2. Minimal Paperwork 3.No Case Interference 4. Consistent Funding Agreements 5. Quick Funding Turnaround 6. Low Funding Rates Prime Case LLC will limit funding to 10%-15% of the case value, to ensure your ability to settle the case will not be compromised. In our experience, plaintiff funding never affects attorney fees or the way your firm handles the case.
Selena Group is a leading global manufacturer of construction chemicals and polyurethane foam, established in 1992 and based in Wrocław, Poland. The company operates in 18–19 countries with around 1,800–2,000 employees and has 30–35 subsidiaries, including manufacturing facilities in Poland, South Korea, China, Romania, Turkey, Spain, Kazakhstan, and Italy. Selena Group is recognized as one of the top four manufacturers of assembly foam and a significant distributor of construction chemicals. Its product range includes high-yield polyurethane foams, sealants, adhesives, waterproofing systems, and thermal insulation solutions. The company operates through four specialized divisions: Interior & Decorations, Windows & Doors, Waterproofing, and Walls, Facades & Chemical Constructions. Selena serves 100 markets worldwide, focusing on professional contractors, industrial users, and home builders, while emphasizing sustainability and innovation in its offerings.
Cameron Ashley Building Products is a prominent omni-channel distributor specializing in roofing, insulation, siding, gypsum, and other specialty building products. The company operates over 45 distribution centers across 26 states, providing more than 4.2 million square feet of storage space. Many of these centers are strategically located near major metropolitan areas, ensuring efficient product availability. The company serves over 5,000 customers in the lumber and building materials industry, including lumberyards, building materials suppliers, and contractors. Cameron Ashley combines distribution center operations with a direct-from-manufacturer approach to enhance supply chain management. This allows them to deliver a wide range of innovative products and services tailored to market needs. Cameron Ashley also fosters a supportive work environment, offering various employee benefits and development programs to prepare future leaders in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.